Long-Term Side Effects of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia. - Wikidata - wikimedia - TriplyDB

Long-Term Side Effects of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia.

Long-Term Side Effects of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia.

http://www.wikidata.org/entity/Q38753313

about

Hepatocellular Toxicity Associated with Tyrosine Kinase Inhibitors: Mitochondrial Damage and Inhibition of Glycolysis.Tyrosine kinase inhibitors: potential use and safety considerations in HIV-1 infection.Bosutinib induced pleural effusions: Case report and review of tyrosine kinase inhibitors induced pulmonary toxicity.Nilotinib Induced Recurrent Gastric Polyps: Case Report and Review of Literature.Genetic predisposition and induced pro-inflammatory/pro-oxidative status may play a role in increased atherothrombotic events in nilotinib treated chronic myeloid leukemia patients.CXorf48 is a potential therapeutic target for achieving treatment-free remission in CML patients.Long-term treatment with bosutinib in a phase 1/2 study in Japanese chronic myeloid leukemia patients resistant/intolerant to prior tyrosine kinase inhibitor treatment.BCR-ABL1 compound mutants display differential and dose-dependent responses to ponatinib.Induction of apoptosis in imatinib sensitive and resistant chronic myeloid leukemia cells by efficient disruption of bcr-abl oncogene with zinc finger nucleases.Ponatinib Activates an Inflammatory Response in Endothelial Cells via ERK5 SUMOylation

P2860

Q33794548-A93D4F25-B30A-48A1-A2B5-76B1C904E81B Q39226064-F4F2226D-79C8-431C-87EA-4730B7A4392E Q39339523-A67DC446-76C4-486B-86E1-F982C9CC6888 Q39433823-D73442C4-BE6B-4F00-989A-FED41C69C215 Q42011392-499B123B-EDEB-43A7-8790-03FA68A41E9C Q47099925-B9CA730A-467C-4C9A-8572-A6FD3FFBABEC Q48275281-ECC48BE3-4D34-40F4-BFEF-FAE1736CF3BF Q49571105-F6CF776E-1E07-4159-BAD4-00A1DD27EB34 Q52648378-6C4ACFF4-F151-4E1B-AE57-528B213E0359 Q58761411-830C3A34-8A29-47A7-8E2C-28A773AABBCC

P2860

Long-Term Side Effects of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia.

http://www.wikidata.org/entity/Q38753313

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Long-Term Side Effects of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia.

@en

type

label

Long-Term Side Effects of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia.

@en

prefLabel

Long-Term Side Effects of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia.

@en

P1433

Q38753313-4E3A13A8-E4AF-4DED-897F-3EF965286862

P1476

Q38753313-2B634BA6-0A5B-4FA2-B895-C9898B5C21D5

P2093

Q38753313-0F7B7081-946D-44E9-BC54-6136D68DD3BA

Q38753313-63F04111-5C04-4C67-A4A5-50FF42E6F7B1

Q38753313-658BE029-1E39-4D2D-B801-7287132D6DAD

Q38753313-AE3E51E6-3E5E-4AB7-A27F-C86AE9CEFD2C

P2860

Q38753313-09B2AC18-0153-4578-9235-D1A8D8A16956

Q38753313-0B78F7A7-648E-4F0B-819E-39C84AA25146

Q38753313-0BCB5182-1A8A-4C55-A87C-AF3DA402854B

Q38753313-16E7E130-7F3D-44AE-94C6-E06CE156327B

Q38753313-18AA98F7-B931-4266-8D56-55D4DA3DCDBA

Q38753313-1A86A920-0D8F-43FA-AA71-7A9D7B4D1DCE

Q38753313-21857EA1-12A1-4E10-8285-B820514AD494

Q38753313-23932A8C-0224-41C0-9244-FF76FCAAB198

Q38753313-24F319E9-7C3F-4A26-BBE9-1F1418111AFF

Q38753313-2541185D-EC93-4BF2-A9C3-711759499AEF

P2888

Q38753313-202F470F-9783-42BD-AB53-AC7CDA42C704

P304

Q38753313-49E69A8F-C9CE-42C6-B353-43FA806F8B60

P31

Q38753313-93049472-6DD2-4889-BA5C-19768F31720F

P356

Q38753313-0D5D9B6D-CA04-4966-B7BE-DB390FDA7063

P433

Q38753313-00447F77-CBD5-4214-8AD9-089BE23FED10

P478

Q38753313-A5A5E54E-5BDB-4D11-BB88-99FBFE06C19D

P577

Q38753313-5A67ACF0-7B52-424C-B2F5-EF5AC414AD83

P6179

Q38753313-166C2AAB-9956-42C3-A820-02ECA6FB165C

P698

Q38753313-53EAA1EA-E050-433B-B712-94FC10EFFC9E

P921

Q38753313-10EA8F8E-60BB-4B60-AFF4-D2E780BA5EC0

P356

S11899-016-0309-2

P1433

Current hematologic malignancy reports

P1476

Long-Term Side Effects of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia.

@en

P2093

John Edwards

http://www.w3.org/2001/XMLSchema#string

Lauren Caldemeyer

http://www.w3.org/2001/XMLSchema#string

Luke Akard

http://www.w3.org/2001/XMLSchema#string

Michael Dugan

http://www.w3.org/2001/XMLSchema#string

P2860

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL

Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22

Comparison of the cancer gene targeting and biochemical selectivities of all targeted kinase inhibitors approved for clinical use

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

Multicenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated With Imatinib

Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV.

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance.

Bleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapy.

P2888

s11899-016-0309-2

P304

71-79

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11899-016-0309-2

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P577

2016-02-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1024613534

http://www.w3.org/2001/XMLSchema#string

P698

26922746

http://www.w3.org/2001/XMLSchema#string

P921

chronic myeloid leukemia